is a prominent clinical-stage, innovative drug development company in China, specializing in novel therapies for diabetes and CNS disorders. Founded in 2010, the company has gained recognition in the Biotechnology, Health Care, Life Sciences, and Pharmaceutical industries. Recently, Series E investment was secured on 29 March 2018. Notably, this round witnessed participation from unknown investors. To maintain global standards, has implemented an internal research quality supervision system Q (QC/QA) based on the advanced open innovation model VIC (VC + IP + CRO). This signifies the company's commitment to ensuring high-quality and innovative solutions in the medical field.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series E | Unknown | - | 29 Mar 2018 | |
| Series D | $117.40M | 10 |
|
27 Mar 2018 |
| Series C | $50.00M | 10 |
|
21 Apr 2016 |
| Series B | $25.00M | 8 |
|
08 Jan 2015 |
| Series A | $50.00M | 6 |
|
20 Sep 2011 |
No recent news or press coverage available for Hua Medicine.
We care about your data, and we'd love to use cookies make your experience better.
